United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the stock in a transaction on Monday, January 26th. The shares were sold at an average price of $471.91, for a total value of $10,617,975.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Tuesday, January 20th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The stock was sold at an average price of $464.66, for a total transaction of $6,795,652.50.
• On Tuesday, January 20th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The stock was sold at an average price of $464.66, for a total value of $3,659,197.50.
• On Monday, January 12th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $479.51, for a total value of $10,788,975.00.
• On Monday, January 5th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total transaction of $3,838,117.50.
• On Monday, January 5th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The stock was sold at an average price of $487.38, for a total transaction of $7,127,932.50.
• On Monday, December 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $502.79, for a total transaction of $11,312,775.00.
• On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $514.35, for a total transaction of $11,572,875.00.
• On Monday, December 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $496.30, for a total transaction of $11,166,750.00.
• On Monday, December 8th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $478.58, for a total value of $10,768,050.00.
• On Monday, December 1st, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $479.91, for a total transaction of $10,797,975.00.

United Therapeutics Price Performance

NASDAQ:UTHR traded down $9.48 during trading hours on Wednesday, reaching $467.30. The company had a trading volume of 274,140 shares, compared to its average volume of 357,474. The firm has a market cap of $20.12 billion, a PE ratio of 17.71, a price-to-earnings-growth ratio of 2.54 and a beta of 0.84. The business’s 50 day moving average price is $487.69 and its 200-day moving average price is $418.26. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.United Therapeutics’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.39 EPS. On average, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of UTHR. Clearstead Advisors LLC increased its position in United Therapeutics by 8.9% during the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 23 shares in the last quarter. Bessemer Group Inc. increased its position in shares of United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after acquiring an additional 28 shares during the last quarter. Archer Investment Corp increased its holdings in United Therapeutics by 9.5% during the 3rd quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 31 shares during the last quarter. F m Investments LLC increased its stake in shares of United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after buying an additional 33 shares during the last quarter. Finally, HB Wealth Management LLC raised its stake in shares of United Therapeutics by 2.9% in the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 35 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of recent research reports. UBS Group raised their target price on United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a report on Wednesday, October 29th. Jefferies Financial Group reissued a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. HC Wainwright boosted their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.